CG Oncology, Inc. Common stock
NASDAQ:CGONBiotechnology
+$1.35 today
- Market cap
- $7.15B
- Beta
- 0.31
- P/E (TTM)
- -28.0
- EPS (TTM)
- -$2.21
Volume 1.79M
Average 1.08M
CGON Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
CG Oncology, Inc. Common stockNASDAQ: CGON
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q3 FY2026 stock-based compensation of $8.46M rose 15.3% year over year, behind the +48.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 41.0% from the prior quarter. Over 3 fiscal years it compounded at +240.5% a year.
Context
- Stock-based compensation amounted to 660.3% of revenue in FY2025, down 340.8 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +15.3% toward the trailing-twelve-month pace of +48.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 26.68M USD
- Year-over-year change
- +134.0%
- 4-year CAGR
- +121.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.68M | +134.0% |
| FY2024 | 2024-12-31 | 11.4M | +646.2% |
| FY2023 | 2023-12-31 | 1.53M | +126.0% |
| FY2022 | 2022-12-31 | 676K | -39.2% |
| FY2021 | 2021-12-31 | 1.11M | — |
Stock-Based Compensation vs competitors
How CGON compares with its peers on the latest reported figures
- CGON's LTM Sep 2026 stock-based compensation of $36.45M is the largest of the 3 companies compared; the peer median is $23.83M.
- Its year-over-year change of +48.9% is the highest of 3, against a peer median of -3.6%.
- Stock-based compensation amounts to 591.2% of revenue for CGON, versus a peer median of 14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $36.45M | +48.9% | +240.5% | 591.2% | |
| LTM Sep 2026 | $34.15M | -8.0% | -2.9% | 18.7% | |
| LTM Mar 2026 | $13.52M | +0.7% | +4.2% | 9.6% | |
| Peer median (excluding CGON) | $23.83M | -3.6% | +0.6% | 14.2% | |
Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.84M) | (35.44M) | (48.61M) | (88.04M) | (161M) |
| Depreciation & Amortization | 10K | 15K | 17K | 32K | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.11M | 676K | 1.53M | 11.4M | 26.68M |
| Change in Working Capital | (1.97M) | 4.44M | 3.44M | 2.91M | 2.28M |
| Accounts Receivables | 0 | 0 | 0 | (689K) | (320K) |
| Inventory | 0 | 0 | 0 | 0 | (444K) |
| Accounts Payables | 578K | (18K) | 2.01M | 3.28M | (1.64M) |
| Other Working Capital | (2.55M) | 4.46M | 1.43M | 320K | 4.68M |
| Other Non-Cash Items | 30K | 509K | (2.06M) | (5.01M) | (1.75M) |
| Operating Cash Flow | (13.65M) | (29.8M) | (45.68M) | (78.71M) | (132.35M) |
| Capital Expenditures | (97K) | (14K) | 0 | (234K) | (134K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (21.97M) |
| Purchases of Investments | 0 | (55.34M) | (517.61M) | (1.05B) | (1.07B) |
| Sales of Investments | 0 | 0 | 396.42M | 745.41M | 844.14M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (97K) | (55.35M) | (121.2M) | (300.76M) | (245.82M) |
| Debt Repayment | 15.2M | 0 | (16.29M) | (365K) | 0 |
| Common Stock Issued | 245K | 166K | 2.08M | 629.47M | 153.59M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (3.42M) | (825K) | 0 |
| Financing Cash Flow | 15.45M | 119.69M | 87M | 628.28M | 153.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.7M | 34.54M | (79.88M) | 248.8M | (224.58M) |
| Free Cash Flow | (13.75M) | (29.82M) | (45.68M) | (78.95M) | (132.48M) |
CG Oncology, Inc. Common stock
NASDAQ:CGON
Intrinsic Alpha fair value
Locked
Current Price
$80.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.